In:
Scientific Reports, Springer Science and Business Media LLC, Vol. 9, No. 1 ( 2019-11-14)
Abstract:
We investigated the diagnostic and prognostic potential of serum N -glycan profiling for castration-resistant prostate cancer (CRPC). We retrospectively investigated serum N -glycan structural analysis by glycoblotting for 287 patients with benign prostatic hyperplasia (BPH), 289 patients with newly diagnosed prostate cancer (PC), 57 patients with PC treated with androgen-deprivation therapy without disease progression (PC-ADT), and 60 patients with CRPC. N -Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N -glycan score) by discriminant analysis based on the combination of 9 N -glycans that were significantly associated with CRPC. The median CRPC N -glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The CRPC N -glycan score could classify CRPC patients with sensitivity, specificity, and area under the curve of 87%, 69%, and 0.88, respectively. The CRPC N -glycan score 〉 1.7 points was significantly associated with poor prognosis in patients with CRPC. The glycoprotein analysis showed that not immunoglobulins but α-1-acid glycoprotein (AGP) were a potential candidate for the carrier protein of N -glycans. The overexpression of specific N -glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC.
Type of Medium:
Online Resource
ISSN:
2045-2322
DOI:
10.1038/s41598-019-53384-y
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2019
detail.hit.zdb_id:
2615211-3
Permalink